Arcellx (NASDAQ:ACLX) (NASDAQ:ACLX) is a clinical-stage biotechnology company dedicated to developing next-generation cell therapies for patients with hematologic malignancies and solid tumors. The company’s proprietary Advanced Receptor Constructs (ARC) platform enables precise control over immune cell activity and persistence, leveraging engineered receptor scaffolds to enhance safety and efficacy. By integrating modular co-stimulatory signals and safety switches into its constructs, Arcellx aims to address key challenges in the field of adoptive cell therapy, including off-tumor toxicity and limited durability of response.
Arcellx’s lead pipeline consists of autologous CAR T-cell candidates targeting CD19 for B-cell non-Hodgkin lymphoma and BCMA for multiple myeloma, both in early-stage clinical development. Preclinical programs extend the ARC platform to solid tumor antigens and investigational natural killer (NK) and macrophage cell therapies, with the objective of broadening applicability across cancer indications. The company collaborates with academic institutions and manufacturing partners to optimize cell expansion processes and accelerate clinical translation of its product candidates.
Founded in 2018 by a team of immunologists and biotechnology entrepreneurs, Arcellx is headquartered in Chicago, Illinois, with research and manufacturing operations in the United States and a strategic presence in Europe. The leadership team combines deep expertise in cell therapy development, translational research and regulatory affairs, drawing on experience from leading biopharmaceutical organizations and academic cancer centers. This collective insight guides the company’s clinical strategy and innovative approach to receptor design.
Since its inception, Arcellx has progressed rapidly from platform validation to first-in-human studies, underscoring its commitment to delivering transformative therapies. As it advances its clinical programs, the company is focused on generating robust safety and efficacy data, expanding manufacturing capacity and forging partnerships to bring its ARC-based cell therapies to patients worldwide.
